Capricor Therapeutics, Inc. (CAPR) Stock: Here’s What’s Happening

0
Biotech Stocks With Potential!

Capricor Therapeutics, Inc. (CAPR) is making a move down in the market in today’s trading session. The stock, focused in the biotechnology industry, is presently priced at $2.48 after falling -4.25% so far in today’s session. In terms of biotechnology companies, there are quite a few aspects that have the ability to lead to price movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines centered around CAPR:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-07-19 12:27PM A Look At Benzinga Pro’s Most-Searched Tickers For October 7, 2019
06:30AM Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
Oct-04-19 10:09AM Zynex (ZYXI) Scales 52-Week High: What’s Driving the Stock?
Oct-02-19 09:15AM Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
Oct-01-19 09:14AM Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System

Nonetheless, any time investors are making a decision to invest, prospective investors should look at much more than just news, especially in the speculative biotechnology sector. Here’s what’s happening with Capricor Therapeutics, Inc..

Recent Movement From CAPR

While a move toward the top in a single session, like what we’re seeing from Capricor Therapeutics, Inc. might cause fear in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It’s generally important to look into trends experienced by the stock further out than a single session. As it relates to CAPR, below are the movements that investors have seen:

  • Past Seven Days – In the last seven days, CAPR has seen a change in price in the amount of -29.75%.
  • Past Month – The monthly ROI from Capricor Therapeutics, Inc. has been -6.06%.
  • Quarterly – In the past quarter, the stock has produced a return on investment that comes to -22.98%
  • Bi-Annually – In the previous 6 months, investors have seen a change of -57.72% from the stock.
  • This Year So Far – Since the the first trading session of this year CAPR has resulted in a return of -39.51%.
  • Full Year – Finally, throughout the past full year, we’ve seen movement that comes to -74.63% from CAPR. Throughout this period of time, the stock has sold at a high price of -78.43% and a low of 7.83%.

Key Ratios

Digging into various key ratios associated with a stock can give prospective traders a look of just how dangerous and/or rewarding a stock pick might be. Below are some of the most important ratios to look at when looking at CAPR.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks tend to carry a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, in regard to Capricor Therapeutics, Inc., it’s short ratio is 0.09.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure If a company is able to cover its debts as they mature based on quick assets or current assets. Because many biotech many companies are heavily reliant on continued investor support, these ratios can look damning. However, quite a few gems in the biotechnology industry do have good quick and current ratios. As far as CAPR, the quick and current ratios work out to 4.20 and 4.20 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets owned by the company to the share price of the stock. In this particular case, that ratio is 0.68.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is a very important ratio to consider. When it comes to CAPR, the cash to share value comes to 1.50.

Analyst Opinions With Regard To Capricor Therapeutics, Inc.

While it’s never a smart idea to blindly follow the opinions of analysts, it is a smart idea to use their analysis in order to validate your own due diligence when it comes to making an investment decision in the biotech space. Here are the most recent moves that we’ve seen from analysts with regard to CAPR.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-26-18 Downgrade Maxim Group Buy → Hold
Jan-26-18 Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17 Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17 Resumed Rodman & Renshaw Buy $14
Jul-06-16 Resumed H.C. Wainwright Buy $13

Smart Money Follows Big Money

An interesting fact that I have learned so far in my brief period on Earth has been that good investors tend to follow the moves made by big money investors. In general, investors that want to keep the risk down will watch investments made by institutional investors as well as those on the inside. So, where is the big money as it relates to CAPR? Here’s what’s happening:

Institutions own 2.30% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 32.93% percent of CAPR shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s The Float Looking Like?

Investors and traders seem to have an interest in the counts of shares both outstanding and available. In terms of Capricor Therapeutics, Inc., currently there are 3.93M and there is a float of 2.63M. These data mean that of the total of 3.93M shares of CAPR in existence today, 2.63M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CAPR, the short percent of the float is 2.82%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.42. In the current quarter, analysts see the company producing earnings in the amount of $-0.70. Over the last 5 years, CAPR has generated revenue in the amount of $27.10% with earnings coming in at 9.40%. On a quarter over quarter basis, earnings have seen movement of 58.30% and revenue has seen movement of 0.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was made by a human and human beings actually play a crucial role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here